Novartis

New Immunotherapy Approach Advances

The new treatment uses T cells, a type of immune cell that are taken from the patient’s body, genetically modified and then reinfused into the patient. These modified T cells are called chimeric antigen receptor (CAR) T cells. In previous trials with these modified T cells, tumor responses have been modest and they did not persist for long enough after being re-introduced into the patient. Using this second generation CAR T cell, Dr. Carl June and his colleagues at Penn obtained long-lasting persistence once the cells were re-introduced.

By |2019-01-18T12:05:26-05:00October 5th, 2012|News|

Life Fest 2006 Video Highlights

Here is a video from Life Fest 2006. The video features speeches from special guest speakers: Josalin Dunn, pediatric GIST patient, Dr. Daniel Vasella, CEO of Novartis, and David Epstein, President of Novartis Oncology: [...]

By |2019-09-25T15:49:51-04:00June 19th, 2006|Video|
Go to Top